M8 Pharmaceuticals said that it has acquired exclusive rights to market Marinomed’s Carragelose nasal spray in Brazil and Mexico. The company will market the product in those countries as Barlo nasal spray for the prevention of respiratory viruses.
Carragelose nasal sprays are currently marketed over 40 countries, including Italy, Austria, Canada, China, and Australia. Marinomed is currently running clinical trials of Carragelose nasal spray for the prevention of SARS-CoV-2 infection and of Inhaleen inhaled Carragelose for the treatment of COVID-19.
M8 CEO Joel Barlan commented, “We are delighted to partner with Marinomed to bring a potential solution to patients in Latin America and provide support in the continued battle to improve the prevention strategies against COVID-19. Our goal is to continue to help improve patient outcomes through our commitment of bringing innovative product to Latin American patients. Our mission is to continue to positively impact the lives patients in Brazil and Mexico.”
Marinomed CEO Andreas Grassauer said, “Carragelose is well established as an efficient means of prevention and treatment against a wide range of respiratory virus infections, including those caused by different coronaviruses. We are very happy that with M8 Pharmaceuticals, we have a strong and experienced partner who will be able to provide our Carragelose based nasal spray in Brazil and Mexico, two important markets.”
Read the M8 Pharmaceuticals press release.
